For emerging or novel viruses like COVID-19, companies are unable to acquire the outbreak strain of virus to test the efficacy of their disinfectant products. Certain countries have policies or general claims that address this (e.g. US EPA Emerging Viral Pathogen Guidance*, EU viral claims) by utilizing a hierarchy of susceptibility of viruses to disinfectants. In general, these policies are based on the ability of a product to kill a ‘harder to kill’ virus and may or may not require preapproval for use in outbreak situations. Care must be taken to use the appropriate dilution at the correct contact time for the suitable application listed on the product label to enable disinfection against SARS-CoV-2. If you are a current customer, you should speak with your account executive for specific information. If you are not a current customer, please visit Ecolab.com to contact us via email or phone.
*In the US a product must be preapproved by US EPA. It must be a hospital disinfectant and carry approved Emerging Viral Pathogen language on the master label.